Biocryst Pharmaceuticals (BCRX) Accounts Payables (2010 - 2026)

Biocryst Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• Quarterly Accounts Payables rose 9.05% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 9.05% YoY) and the FY2025 annual result came in at $15.8 million, up 35.92% from the prior year.
• Accounts Payables was $11.0 million for Q1 2026 at Biocryst Pharmaceuticals, down from $15.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $20.9 million in Q4 2023 and bottomed at $5.6 million in Q3 2025.
• A 5-year average of $11.5 million and a median of $11.6 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables jumped 90.44% — and 2025, when it plunged 58.71%.
• Biocryst Pharmaceuticals' Accounts Payables stood at $14.4 million in 2022, then surged by 45.53% to $20.9 million in 2023, then slumped by 44.27% to $11.6 million in 2024, then soared by 35.92% to $15.8 million in 2025, then sank by 30.76% to $11.0 million in 2026.
• Business Quant data shows BCRX's Accounts Payables at $11.0 million in Q1 2026, $15.8 million in Q4 2025, and $5.6 million in Q3 2025.